[Long-term results of xenoscleroplasty of the posterior pole of the eyeball in the treatment of patients with progressive myopia].

The study deals with the development of an effective, atraumatic and easy-to-use treatment for patients with progressive myopia, by using a discoid xenograft. The treatment involves implantation of a discoid xenograft to the episclera of the posterior pole of the eye. The xenograft is a white disk prepared from the treated bovine pericardium and it has 2 mm in thickness and a diameter of 13 mm. Clinical studies were performed in 89 patients (161 eyes) operated on by the proposed procedure, by evaluating the stabilized progression of myopia 4 years later. In the late period of a follow-up, the stabilization effect was 88.3 to 92.6% in relation to the degree of myopia. There was evidence for increases in the thickness of the sclera (and its acoustic density) on the posterior pole of the eye, for improved regional hemodynamics and better electrophysiological functions of the retina in the postoperative period. Xenoscleroplasty of the posterior pole of the eye with a bovine pericardial xenograft is an easy-to-use, pathogenetically oriented, highly effective, and safe treatment in patients with progressive myopia.

[Mechanism of specific vaccine therapy in ocular herpes simplex]. / O mekhanizme spetsificheskoi vaktsinoterapii pri gerpeticheskoi bolezni glaz.

The mechanism of specific vaccine therapy in herpetic eye disease was studied. The effectiveness of the therapy in the observation period of 3 to 8 years was established. In 71 (62%) of 114 patients relapses of the disease disappeared completely, in 32 (26%) became less frequent and in 11 (10%) their frequency did not change. The clinical course of relapses in all cases became milder. The vaccination courses given were shown not to influence the level of virusneutralizing antibody but to induce the appearance in the lacrimal fluid of immunoglobulins G and M and to increase considerably the level of IgA. The vaccint therapy enhanced the reactions of cell-mediated immunity which was manifested in increased specific blasttransformation of lymphocytes (up to 18%) and reduced the migrational capacity of leucocytes to inactivated antigen of herpesvirus. The effect of the vaccine persisted only for a few months. The immunological and clinical analyses showed that it was expedient to give vaccine in courses at 6--12-month intervals after an attack of herpes.